Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0000320017-25-000060
Q2 2024 · 10-Q
Revenue$70.00K$70.00K — vs Q2 2023no prior Q1 2024 on file
Net Income-$4.66M-$4.66M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.54-$0.54 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$4,868,000N/M
Operating Cash Flowderived-$3,956,000N/M
Free Cash Flowderived-$3,956,000N/M
Margins · derived
Operating margin-6954.3%
Net margin-6655.7%
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $70.00K | $0.00 | $0.00 | — |
| Net Income | -$4.66M | -$5.04M | -$4.03M | -$6.63M |
| EPS Diluted | -$0.54 | -$0.61 | -$0.50 | -$1.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR